IRLAB Therapeutics – executive interview

Published on 17 November 2022

Based in Sweden, IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson’s disease (PD) and other CNS disorders. Its two lead assets are mesdopetam (D3-receptor antagonist for levodopa-induced dyskinesias in PD) and pirepemat (PFC enhancer for impaired balance and falls). Mesdopetam is an oral D3 antagonist and has just completed recruitment in a Phase IIb trial for levodopa-induced dyskinesias in PD, with top-line data anticipated around year end. Pirepemat is an oral prefrontal cortex enhancer in a Phase IIb trial for the treatment of impaired balance and falls in PD. IRLAB is also developing a preclinical pipeline of drug candidates (IRL942 and IRL757) for the non-motor symptoms of PD and a potential once-daily treatment for PD without complications (P003). The company remains well funded in the medium term.

In this video, CEO Richard Godfrey provides an update on IRLAB’s pipeline and upcoming milestones.

Share this with friends and colleagues